The Meisenheimer Complex as a Paradigm in Drug Discovery: Reversible Covalent Inhibition through C67 of the ATP Binding Site of PLK1

Alexandru, 2001, Phosphorylation of the cohesin subunit Scc1 by Polo/Cdc5 kinase regulates sister chromatid separation in yeast, Cell, 105, 459, 10.1016/S0092-8674(01)00362-2 Baillie, 2016, Targeted covalent inhibitors for drug design, Angew. Chem. Int. Ed., 55, 13408, 10.1002/anie.201601091 Bunting, 1979, Heterocyclic Meisenheimer complexes, Adv. Heterocycl. Chem., 25, 67 Cohen, 2005, Structural bioinformatics-based design of selective, irreversible kinase inhibitors, Science, 308, 1318, 10.1126/science1108367 Craig, 2014, Current assessment of polo-like kinases as anti-tumor drug targets, Expert Opin. Drug Discov., 9, 773, 10.1517/17460441.2014.918100 de Carcer, 2011, Plk5, a polo box domain-only protein with specific roles in neuron differentiation and glioblastoma suppression, Mol. Cell. Biol., 31, 1225, 10.1128/MCB.00607-10 Dohner, 2014, Randomized, phase 2 trial comparing low-dose cytarabine with or without volasertib in AML patients not suitable for intensive induction therapy, Blood, 124, 1426, 10.1182/blood-2014-03-560557 Elez, 2000, Polo-like kinase 1, a new target for antisense tumor therapy, Biochem. Biophys. Res. Commun., 269, 352, 10.1006/bbrc.2000.2291 Elez, 2003, Tumor regression by combination antisense therapy against Plk1 and Bcl-2, Oncogene, 22, 69, 10.1038/sj.onc.1206038 Elia, 2003, Proteomic screen finds pSer/pThr-binding domain localizing Plk1 to mitotic substrates, Science, 299, 1228, 10.1126/science.1079079 Elia, 2003, The molecular basis for phosphodependent substrate targeting and regulation of Plks by the Polo-box domain, Cell, 115, 83, 10.1016/S0092-8674(03)00725-6 Feng, 2016, Access to a new class of synthetic building blocks via trifluoromethoxylation of pyridines and pyrimidines, Chem. Sci., 7, 424, 10.1039/C5SC02983J Gjertsen, 2014, Discovery and development of the Polo-like kinase inhibitor volasertib in cancer therapy, Leukemia, 29, 11, 10.1038/leu.2014.222 Glover, 1998, Polo-like kinases: a team that plays throughout mitosis, Genes Dev., 12, 3777, 10.1101/gad.12.24.3777 Golan, 2002, The cyclin-ubiquitin ligase activity of cyclosome/APC is jointly activated by protein kinases Cdk1-cyclin B and Plk, J. Biol. Chem., 277, 15552, 10.1074/jbc.M111476200 Hamanaka, 1995, Polo-like kinase is a cell cycle-regulated kinase activated during mitosis, J. Biol. Chem., 270, 21086, 10.1074/jbc.270.36.21086 Jang, 2002, Functional studies on the role of the C-terminal domain of mammalian polo-like kinase, Proc. Natl. Acad. Sci. USA, 99, 1984, 10.1073/pnas.042689299 Kloss, 2017, In vivo dearomatization of the potent antituberculosis agent BTZ043 via Meisenheimer complex formation, Angew. Chem. Int. Ed., 56, 2187, 10.1002/anie.201609737 Knecht, 1999, Prognostic significance of polo-like kinase (PLK) expression in squamous cell carcinomas of the head and neck, Cancer Res., 59, 2794 Kotani, 1998, PKA and MPF-activated polo-like kinase regulate anaphase-promoting complex activity and mitosis progression, Mol. Cell, 1, 371, 10.1016/S1097-2765(00)80037-4 Lee, 1998, Mutation of the polo-box disrupts localization and mitotic functions of the mammalian polo kinase Plk, Proc. Natl. Acad. Sci. USA, 95, 9301, 10.1073/pnas.95.16.9301 Lee, 1995, Plk is an M-phase-specific protein kinase and interacts with a kinesin-like protein, CHO1/MKLP-1, Mol. Cell. Biol., 15, 7143, 10.1128/MCB.15.12.7143 Leung, 2002, The Sak polo-box comprises a structural domain sufficient for mitotic subcellular localization, Nat. Struct. Biol., 9, 719, 10.1038/nsb848 McInnes, 2006, Inhibitors of Polo-like kinase reveal roles in spindle-pole maintenance, Nat. Chem. Biol., 2, 608, 10.1038/nchembio825 McInnes, 2011, PLK1 as an oncology target: current status and future potential, Drug Discov. Today, 16, 619, 10.1016/j.drudis.2011.05.002 Nurse, 1990, Universal control mechanism regulating onset of M-phase, Nature, 344, 503, 10.1038/344503a0 Roshak, 2000, The human polo-like kinase, PLK, regulates cdc2/cyclin B through phosphorylation and activation of the cdc25C phosphatase, Cell. Signal., 12, 405, 10.1016/S0898-6568(00)00080-2 Seong, 2002, A spindle checkpoint arrest and a cytokinesis failure by the dominant-negative polo-box domain of Plk1 in U-2 OS cells, J. Biol. Chem., 277, 32282, 10.1074/jbc.M202602200 Singh, 1997, Structure-based design of a potent, selective, and irreversible inhibitor of the catalytic domain of the erbB receptor subfamily of protein tyrosine kinases, J. Med. Chem., 40, 1130, 10.1021/jm960380s Smith, 1997, Malignant transformation of mammalian cells initiated by constitutive expression of the polo-like kinase, Biochem. Biophys. Res. Commun., 234, 397, 10.1006/bbrc.1997.6633 Spankuch-Schmitt, 2002, Effect of RNA silencing of polo-like kinase-1 (PLK1) on apoptosis and spindle formation in human cancer cells, J. Natl. Cancer Inst., 94, 1863, 10.1093/jnci/94.24.1863 Spankuch-Schmitt, 2002, Downregulation of human polo-like kinase activity by antisense oligonucleotides induces growth inhibition in cancer cells, Oncogene, 21, 3162, 10.1038/sj.onc.1205412 Sumara, 2004, Roles of polo-like kinase 1 in the assembly of functional mitotic spindles, Curr. Biol., 14, 1712, 10.1016/j.cub.2004.09.049 Takahashi, 2003, Polo-like kinase 1 (PLK1) is overexpressed in primary colorectal cancers, Cancer Sci., 94, 148, 10.1111/j.1349-7006.2003.tb01411.x Taylor, 2008, Ligand discovery and virtual screening using the program LIDAEUS, Br. J. Pharmacol., 153, S55, 10.1038/sj.bjp.0707532 Taylor, 1970, Novel Meisenheimer complexes, alkyl-2,4,6-trinitrocyclohexadienate anions, J. Org. Chem., 35, 3578, 10.1021/jo00835a093 Tokumitsu, 1999, Prognostic significance of polo-like kinase expression in esophageal carcinoma, Int. J. Oncol., 15, 687 Toyoshima-Morimoto, 2002, Plk1 promotes nuclear translocation of human Cdc25C during prophase, EMBO Rep., 3, 341, 10.1093/embo-reports/kvf069 Wagner, 1973, Benzthiazol-N-oxide, I. Synthese und Reaktivität von 2-Alkoxycarbonyl-benzthiazol-N-oxiden, Chem. Ber., 106, 640, 10.1002/cber.19731060230 Wagner, 1976, Benzothiazol-N-oxide, IV1) Synthese und Reaktivität von 2-Cyanbenzothiazol-N-Oxiden und 2-Benzothiazolcarbonitrilen, Chem. Ber., 109, 611, 10.1002/cber.19761090224 Wolf, 1997, Prognostic significance of polo-like kinase (PLK) expression in non-small cell lung cancer, Oncogene, 14, 543, 10.1038/sj.onc.1200862 Wu, 2003, Discovery of a novel family of CDK inhibitors with the program LIDAEUS: structural basis for ligand-induced disordering of the activation loop, Structure, 11, 399, 10.1016/S0969-2126(03)00060-1 Yuan, 1997, Polo-like kinase, a novel marker for cellular proliferation, Am. J. Pathol., 150, 1165 Yuan, 2011, Polo-box domain inhibitor poloxin activates the spindle assembly checkpoint and inhibits tumor growth in vivo, Am. J. Pathol., 179, 2091, 10.1016/j.ajpath.2011.06.031 Zhao, 2017, Determining cysteines available for covalent inhibition across the human kinome, J. Med. Chem., 60, 2879, 10.1021/acs.jmedchem.6b01815